Pharma Pulse 10/15/24: Today’s Playbook for Startups, Key End Points in Clinical Trials & more

‘Selling a Vision’: Today’s Playbook for Startups

The Big Pharma commercialization playbook doesn’t work for emerging life sciences companies bootstrapping their way up. Exploring three strategies that could be the ingredients of a winning formula for startups.

Key End Points in Clinical Trials

Panelists discuss how clinical trials in multiple myeloma can be improved to better reflect real-world scenarios and patient outcomes, emphasizing the importance of end points such as progression-free survival, overall survival, and quality of life measures, while also considering ways to increase trial inclusivity and applicability to diverse patient populations.

This AI Pioneer Thinks AI Is Dumber Than a Cat

Yann LeCun, an NYU professor and senior researcher at Meta Platforms, says warnings about the technology’s existential peril are ‘complete B.S.’

Humana Partnership With Volunteers of America Expands Access to Integrated Healthcare for Historically Unsupported Communities

Leading health and well-being company Humana Inc., continues to focus on advancing health equity with significant commitments to local affiliates of Volunteers of America (VOA).

Nicholas Saraceno on LinkedIn
Checking in live from #AccessInsight shere in DC! I’ll be providing session coverage and video interviews on behalf of Pharmace utical Commerce Magazine (who is also a conference sponsor) and really looking forward to learning about the latest data-driven access and commercialization tactics, so stay tuned. IntegriChain Blue Fin Group, an IntegriChain Company

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs